Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
On Tuesday, Piper Sandler confirmed its positive stance on Stryker Corporation (NYSE:SYK), a leading medical technology company with a market capitalization of $140.44 billion, by maintaining an Overweight rating and a price target of $420.00. According to InvestingPro analysis, Stryker maintains a "GREAT" financial health score and has consistently paid dividends for 35 consecutive years. The company is poised to capitalize on robust market growth and incremental market share gains in certain sectors, including the recent launch of Artix in the PAO (periacetabular osteotomy) space.
The firm’s analysts project that Stryker will continue to exhibit some of the strongest growth rates within the large cap, diversified medtech sector, building on its impressive 10.23% revenue growth over the last twelve months to $22.59 billion. This forecast is based on expected annual procedure volumes for Stryker from 2025 to 2027, as gathered from respondents’ data. The anticipated volume for this year stands at 1,368 million procedures, marking a 14.0% increase compared to 2024.
Looking ahead to 2026 and 2027, the procedure volumes are expected to rise to 1,534 million and 1,734 million, respectively, translating to year-over-year growth of 12.1% to 13.1%. Despite initial concerns of market share erosion following Stryker’s acquisition activities, the actual impact appears to be limited to the PE (pulmonary embolism) space. Share gains in DVT (deep vein thrombosis) and PAO, coupled with general market growth in peripheral thrombectomy, are anticipated to bolster Stryker’s weighted average market growth rate in the forthcoming years.
As a result of these factors, Piper Sandler foresees Stryker maintaining a strong top-line growth profile, which is considered to be among the best in its category. The company’s strategy of expanding its market presence in specific high-growth areas is expected to underpin its continued success in the medical technology industry. Based on InvestingPro data, analysts maintain a bullish consensus on the stock, with price targets ranging from $276 to $465. For deeper insights into Stryker’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Stryker Corporation has completed its $4.94 billion acquisition of Inari Medical (TASE:BLWV), marking a significant expansion in its product portfolio. This strategic move is expected to enhance Stryker’s offerings in the medical instruments sector. The acquisition is projected to contribute $590 million in revenue for the 10-month period in 2025, although it may slightly dilute Stryker’s operating margins. Citi has responded positively to this acquisition by initiating a Buy rating for Stryker with a price target of $450, highlighting the potential of Inari’s products in the underpenetrated venous thromboembolism market.
Additionally, Stryker has issued $3 billion in new debt to finance the Inari acquisition, with the notes maturing between 2027 and 2035. This financial strategy underscores Stryker’s commitment to managing its capital structure while pursuing growth opportunities. In other developments, Stryker introduced the Sync Badge, a hands-free communication device for healthcare teams, aiming to improve coordination and patient care. The company also launched the Steri-Shield 8 PPE system, featuring enhanced protection and comfort for healthcare professionals. These product innovations reflect Stryker’s ongoing efforts to advance medical technology and support healthcare providers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.